Biological Behavior of Papillary Carcinoma of the Thyroid Including Squamous Cell Carcinoma Components and Prognosis of Patients Who Underwent Locally Curative Surgery by Ito, Yasuhiro et al.
Hindawi Publishing Corporation
Journal of Thyroid Research
Volume 2012, Article ID 230283, 5 pages
doi:10.1155/2012/230283
Clinical Study
BiologicalBehavior ofPapillaryCarcinomaoftheThyroid
IncludingSquamous CellCarcinoma Componentsand Prognosis
of Patients Who UnderwentLocallyCurative Surgery
Yasuhiro Ito,1 Mitsuyoshi Hirokawa,2 Takuya Higashiyama,1
Minoru Kihara,1 Chisato Tomoda,1 YuukiTakamura,1 Kaoru Kobayashi,1
AkihiroMiya,1 andAkiraMiyauchi1
1Department of Surgery, Kuma Hospital, Shimoyamate-Dori, Chuo-Ku, Kobe 650-0011, Japan
2Department of Pathology, Kuma Hospital, Kobe 650-0011, Japan
Correspondence should be addressed to Yasuhiro Ito, ito01@kuma-h.or.jp
Received 21 June 2011; Accepted 18 July 2011
Academic Editor: Nikola Beˇ siˇ c
Copyright © 2012 Yasuhiro Ito et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thyroid carcinoma showing squamous diﬀerentiation throughout the entire lesion is diagnosed as squamous cell carcinoma of
the thyroid (SCCT) in the WHO classiﬁcation. This entity is a rare disease and shows a dire prognosis; however, squamous
diﬀerentiationismorefrequentlydetectedinonlyaportionofpapillarythyroidcarcinoma.Inthispaper,wepresentourexperience
of 10 patients (8 primary lesions and 2 with recurrence in the lymph nodes) with papillary thyroid carcinoma having an SCC
component (PTC-SCC). Only 3 of 8 primary lesions (38%) and none of the 2 recurrent nodes were preoperatively diagnosed
as or suspected of having SCC components. All 10 patients underwent locally curative surgery. To date, 3 patients have died of
carcinoma, and 2 had distant metastasis at diagnosis or had an undiﬀerentiated carcinoma component. The other 7 are currently
alive 5 to 43 months after diagnosis. Systemic adjuvant therapy after the detection of recurrence was eﬀective for 2 patients. It is
possible that some PTC-SCC patients without distant metastasis who undergo locally curative surgery can survive for a prolonged
period and adjuvant therapies can be eﬀective for local and distant recurrences.
1.Introduction
Squamous cell carcinoma of the thyroid (SCCT) is known to
show very aggressive characteristics and a dire prognosis. In
the WHO classiﬁcation [1], SCCT is deﬁned as “squamous
cell carcinoma of the thyroid should be composed entirely
o ft u m o u rc e l l sw i t hs q u a m o u sd i ﬀerentiation.” According
to this deﬁnition, SCCT is an extremely rare disease [2–5].
However, squamous diﬀerentiation can be more frequently
observed as a SCC component in a portion of the papillary
carcinoma (PTC) lesion, especially in the tall cell variant
[6]. Most previous studies investigating a comparably large
number of patients investigated SCCT and PTC with an SCC
component(PTC-SCC)asasinglegroup,andourknowledge
regarding the biological characteristics of PTC-SCC remains
poor because of its rarity. To date, we have encountered
10 patients who were diagnosed as having PTC-SCC on
postoperative pathological examination. In this study, we
present their clinicopathological features, therapies, and
clinical outcomes to elucidate the biological behavior of this
disease.
2. Patients andMethods
Wereviewedthesurgicalandpathologicalrecordsofpatients
who underwent surgery for thyroid carcinoma between 2006
and 2010. In this period, 5749 patients underwent surgery
for primary or recurred PTC. Of these, 10 patients (0.2%)
were diagnosed as PTC-SCC and were enrolled in this
study. In this period, no patients were diagnosed as SCCT.
These diagnoses were rereviewed by a thyroid pathologist
(M.H.) based on the WHO classiﬁcation [1]. PTC-SCC was
diagnosedin8primarylesionsobtainedatinitialsurgeryand2 Journal of Thyroid Research
2recurrentlymphnodesobtainedatsecondsurgery.Patients
who had SCC sites other than the thyroid were excluded
from the series. Patients who were diagnosed as having PTC
with squamous cell metaplasia (squamous lesions appear
benign) or squamoid subtype in undiﬀerentiated carcinoma
(UC) were excluded from the study. In this period, 3 patients
were suspected as having PTC-SCC (1 primary lesion and 2
recurring lesions) but underwent biopsy only. One patient
died of carcinoma one month after detection, and two
patients were referred to other hospitals, and their prognoses
are unknown. These patients were also excluded from the
study. In our department, all patients with PTC undergo
thyroidultrasonography,andneckCTscanisalsoperformed
forthosewhohaveclinicallymphnodemetastasisandwhose
primarylesionsaresuspectedofhavingextensiontoadjacent
organs. All patients in our series also underwent ultrasonog-
raphy. Neck CT scan (plain and enhanced) was performed
for 9 patients. Furthermore, all patients underwent chest CT
scan to screen for lung metastasis and 3 patients who were
cytologically suspected of having SCC or UC also underwent
abdominal CT scan also. None of these patients underwent
PET-CT preoperatively, although two underwent PET-CT
after surgery. All patients underwent ultrasound-guided ﬁne
needleaspirationbiopsy(FNAB)fordiagnosis.Furthermore,
3 patients who were suspected of SCC or UC on cytology
underwentalsoultrasound-guidedcoreneedlebiopsy(CNB)
to conﬁrm the diagnosis. None of these patients showed
any complications of CNB, such as hemorrhage, hematoma,
and recurrent laryngeal nerve paralysis. On pathological
examination, UC lesion was also detected in 2 patients (one
primary lesion and one recurrent lymph node). One patient
also had primary lung carcinoma, which was detected on
CT scan before thyroid surgery. After thyroid surgery, this
patient was referred to another hospital and underwent
surgeryandchemotherapyforlungcarcinoma.Thehistology
of lung carcinoma was adenocarcinoma.
3. Results
We analyzed the backgrounds and preoperative ﬁndings on
imaging studies of 10 PTC-SCC (Table 1). Patients consisted
of 7 females and 3 males, and patient ages ranged from 68
to 83 years. Of 8 patients who underwent initial surgery,
only 3 (38%) (patient nos. 1, 4, and 8) were preoperatively
diagnosed as or suspected of having an SCC component on
FNAB or CNB. Tumors of these 3 patients were suspected
to signiﬁcantly extend to adjacent organs. Therefore, these
patients underwentchemotherapyusing paclitaxel [7]bef o r e
surgery, considering the possibility of UC with Stage IVB
[8], to promote tumor shrinkage and make locally curative
surgery easier. There was no evidence of carcinoma progres-
sion during preoperative chemotherapy, although no patients
werejudgedascompleteresponse(manuscriptinpreparation).
The remaining 5 primary lesions were diagnosed as PTC on
cytology. Tumor size ranged from 3.5 to 5.6cm, and 7 of
these patients also had lymph node metastasis detected on
preoperative imaging studies. Three patients (patient nos. 6,
7, and 8) also underwent FNAB for metastatic nodes and
were diagnosed as or suspected of having PTC. Two patients
(patients nos. 2 and 3) had previously undergone initial
surgery for PTC, and recurrence was detected in the lymph
nodes, which measured 0.9cm and 3.9cm, respectively. The
cytological results of these nodes were PTC and UC, respec-
tively.Twopatients(patientnos.1and3)hadlungmetastasis
at surgery, and one (patient no. 10) had primary lung
carcinoma that was treated after surgery for thyroid carci-
noma at another hospital, as indicated above.
Table 2 summarizes the intraoperative and postoperative
ﬁndings and clinical courses of these 10 patients. All 8
primary lesions showed signiﬁcant extrathyroid extension
corresponding to T4a in the UICC TNM classiﬁcation [8],
but all these patients could undergo locally curative surgery.
Of 8 patients, 2 (patient nos. 4 and 5) were SCC dominant,
and the remaining 6 (patient nos. 1, 6–10) were PTC dom-
inant on pathological examination for primary lesions. PTC
lesion was dominant in 2 patients who underwent surgery
for lymph node recurrence (patient nos. 2 and 3). The range
of the portion of SCC component was less than 10% in 2
patients (patient nos. 2 and 6), 10–20% in 5 patients (patient
nos. 1, 7–10), and 40% or more in 3 patients (patient nos. 3–
5). The PTC lesions of 4 patients (50%) were tall cell variant.
Two patients (patient nos. 3 and 4) also demonstrated UC
lesion.
None of these 10 patients underwent radioactive iodine
(RAI) therapy after surgery. The 3 patients who underwent
preoperative chemotherapy continued to receive it after
surgery.Chemotherapy wasinitiated aftersurgeryforpatient
nos. 3 and 5. Patient no. 3 underwent chemotherapy
immediately after initial surgery because of lung metastasis
and involvement of a UC component and patient no. 5
underwent chemotherapy after the detection of local recur-
rence. Patient no. 9 showed recurrence in the lung 3 months
aftersurgeryandunderwentimmunotherapyusingdendritic
cells pulsed with WT1 peptide at the patient’s request [9].
Three patients (patients nos. 5, 7, and 8) underwent external
beam radiotherapy (EBRT) of the whole neck at 50–60Gy
immediately after surgery. However, 2 local recurrences were
detected during EBRT in patient no. 5. One was located
in front of the common carotid artery and was diagnosed
as SCC on CNB, and another was found in the skin, for
which neither FNAB nor CNB was performed. The former
disappeared by postoperative chemotherapy, and the latter
was resected by second surgery. The histology of the second
surgical specimen was SCC.
During followup, patient no. 1, who had lung metastasis
at surgery, developed recurrence in the bone and died of
carcinoma 18 months after diagnosis because of the enlarge-
ment of lung metastasis. Patient no. 3 is currently alive
despite the development of lung metastasis that had been
present before surgery. Patient no. 4, who had a UC com-
ponent, developed recurrence in the larynx and underwent
a second surgery at another hospital. The recurrent tumor
was pathologically diagnosed as UC, and this patient died
of UC progression 23 months after diagnosis. In patient
no. 5, there has been no further evidence of carcinoma
recurrence to date after chemotherapy and second surgery.Journal of Thyroid Research 3
Table 1: Backgrounds and preoperative evaluation of 10 patients with PTC-SCC.
Patient
no. Gender Age Initial
surgery?
Rapid
growth
∗Preoperative
diagnosis
(primary)
∗Preoperative
diagnosis (LN
meta)
Tumor size
(cm)
LN meta
size (cm)
Distant
metastasis
at surgery
1 Female 71 Yes Yes? SCC x 5.6 1.6 Lung
2F e m a l e 7 1 N o N o x P T C x 0 . 9 N o
3 Female 69 No Yes x UC x 3.9 Lung
4 Female 67 Yes No UC or SCC x 4.9 x No
5 Female 83 Yes No PTC or PDC x 5.2 1.7 No
6 Male 76 Yes No PTC PTC 4.0 1.4 No
7 Male 71 Yes No PTC PTC 3.5 0.9 No
8 Female 68 Yes No PTC or SCC PTC? 4.4 2.7 No
9 Male 70 Yes No PTC x 4.4 3.6 No
∧10 Female 71 Yes No PTC x 4.7 2.7 No
PTC: papillary thyroid carcinoma, UC: undiﬀerentiated carcinoma; PDC: poorly diﬀerentiated carcinoma, SCC: squamous cell carcinoma.
∗B a s e do nF N A Bo rC N B .
∧Also had lung carcinoma.
Table 2: Intraoperative and pathological ﬁndings and prognosis of 10 patients with PTC-SCC.
Patient
no.
Surgical
designs Resection Extrathyroid
extension
Pathology
(primary)
Pathology
(LN meta)
Adjuvant
therapies
Carcinoma
recurrence
Outcome
after
diagnosis
1T T + M N D R 0 ? Y e s
∗∗PTC > SCC
(10%) PTC ∗chemo Bone 18m DOC
2C T + M N D R 0 x xPTC > SCC
(<10%) xx 43m
ANEC
3M N D R 0 x x PTC > SCC
(40%) > UC Chemo x 33m AWC
4T T + C N D R 0 Y e s SCC (40%) >
UC > PTC PTC ∗chemo
∧Laryn,
Bone 23m DOC
5T T + M N D R 0 Y e s SCC (80%) >
PTC (tall) PTC Chemo + EBRT Skin, local 18m
ANEC
6T T + M N D R 0 ? Y e s PTC > SCC
(<10%) PTC x x 14m
ANEC
7T T + M N D R 0 Y e s PTC (tall) >
SCC (40%) PTC EBRT x 13m
ANEC
8L I + M N D R 0 Y e s PTC (tall) >
SCC (10%) PTC ∗chemo + EBRT x 9m ANEC
9T T + M N D R 0 Y e s PTC (tall) >
SCC (20%) PTC Immunotherapy Lung 9m DOC
10 TT + MMD R1 Yes PTC > SCC
(20%) PTC Chemo for lung
carcinoma x5 m A N E C
∗Preoperative chemotherapy was also performed. ∧Recurrence of UC. ∗∗A > B indicates A occupied a larger portion than B.
TT: total thyroidectomy, CT: completion total thyroidectomy, LI: lobectomy with is thymectomy, CND: central node dissection, MND: modiﬁed radical neck
dissection, EBRT; external beam radiotherapy.
DOC; Died of carcinoma.
ANEC: Alive with no evidence of Carcinoma.
AWC: Alive with carcinoma.
Lung metastasis was stable in patient no. 9 for 6 months
after the initiation of immunotherapy, but he died of sudden
respiratory tract hemorrhage 9 months after surgery. The
remaining 5 (patients nos. 2, 6–8, 10) are currently alive with
noevidenceofcarcinomarecurrence,althoughpatientno.10
is currently undergoing chemotherapy for lung carcinoma.
4. Discussion
In this study, we demonstrated that it is diﬃcult to diagnose
P T C - S C Co np r e o p e r a t i v eF N A Bo rC N B .O n l y3o f8
patients (38%) having primary lesions were preoperatively
diagnosed as or suspected of having SCC components. This4 Journal of Thyroid Research
is partially because of the diﬃculty in diﬀerential diagnosis
between SCC and UC on cytology. Furthermore, SCC cells
may not be aspirated or biopsied if the needle does not
appropriately hit SCC components. In our series, all patients
were older, 7 patients had carcinoma larger than 4cm,
clinical node metastasis was detected in 7 patients, all had
signiﬁcant extrathyroid extension, and the PTC lesions of
4 patients were diagnosed as tall cell variant. These clini-
copathological features were recognized as predicting poor
prognosis, indicating that squamous diﬀerentiation occurs
in PTC with biologically aggressive behavior [10–13].
Previous studies investigated SCCT and PTC-SCC as a
single group and demonstrated that most of these patients
showed a poor prognosis. Booya et al. showed that the
median survival period was only 8.6 months for 10 patients
[2]. According to a review by Syed et al. in 2010 [14], median
survival periods in reports published between 1985 and 2009
ranged from 3 to 24 months but mostly 12 months or
even shorter. Furthermore, Cook et al. demonstrated that all
patientswithSCCTorPTC-SCCwhounderwentincomplete
resection or biopsy died within a short period despite
adjuvanttherapies[3],whichwassimilartotheresultsofUC,
as we previously demonstrated [15].
In this study, we investigated 10 patients with PTC-SCC
who underwent locally curative resection, indicating that
they were potential long-term survivors. In our series, 7
patients have survived for 8 months to 43 months to date.
Two patients (patients nos. 2 and 6) with only focal SCC
lesions who did not show distant metastasis at diagnosis
have survived without any further recurrence for 14 and
43 months after diagnosis, respectively, although they
underwent no adjuvant therapies. The remaining 5 with
larger lesions of SCC components, who underwent either
or both chemotherapy and EBRT, have also survived with
or without recurrence. Of the 3 patients who died of
carcinoma, 2 had distant metastasis at diagnosis or had a UC
component. These ﬁndings suggest that long-term survival
can be expected for some PTC-SCC patients if they undergo
locally curative surgery and do not have distant metastasis at
diagnosis or a UC component.
Previous studies demonstrated controversial results of
adjuvant chemotherapy [16–18]. In our series, 3 patients
who were cytologically diagnosed as or suspected of having
SCC underwent preoperative adjuvant chemotherapy. These
tumors were large and were suspected of extending to
adjacent organs. In order to make locally curative surgery
easier, we performed preoperative chemotherapy based on
the protocol for UC [7]. If a tumor is small without the
suspicion of extrathyroid extension and locally curative
surgery is expected to be easy, immediate surgery may be
preferred to avoid losing time. Postoperative chemotherapy
shouldbeperformedforpatientshavingdistantmetastasisat
surgery or those who have undergone only palliative surgery.
It remains unclear whether chemotherapy immediately
after locally curative surgery for patients without distant
metastasis is eﬀective to prolong the survival of PTC-SCC
patients, because we did not perform a comparative study.
However, it may be an alternative in order to control minute
carcinoma lesions that remained unresected in local lesions
and micrometastases in distant organs. Another strategy is to
initiate chemotherapy when recurrence is clinically detected.
Since one of the local recurrences disappeared in patient no.
5, this may also promise a certain level of eﬀect.
EBRT is another adjuvant therapy for local control.
However, previous studies of SCCT and PTC-SCC showed
controversial ﬁndings of its eﬀectiveness [2, 3, 18, 19]. In our
series, 3 patients underwent EBRT immediately after surgery.
Two patients showed no evidence of local recurrence, but in
1 patient, local recurrences became apparent during EBRT.
Therefore, we cannot conclude that EBRT has a signiﬁcant
eﬀect on the local control of PTC-SCC. However, it may
be better to perform postoperative EBRT, especially for
cases with signiﬁcant extension to adjacent organs, because
multimodality therapy should be considered for aggressive
diseases such as PTC-SCC.
In summary, we have presented our experience of treat-
ing 10 patients with PTC-SCC, which is diﬃcult to diagnose
preoperatively. Long-term survival can be expected for PTC-
SCC patients if locally curative resection can be performed
and distant metastasis at surgery is not detected. Adjuvant
chemotherapy and EBRT may contribute to the control of
carcinoma recurrence, but further studies of a large number
ofpatientsarenecessarytoestablishtherapeuticprotocolsfor
PTC-SCC patients.
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